Antibody drug conjugates: hitting the mark in pancreatic cancer?

Pancreatic cancer is one of the most common causes of cancer-related death, and the 5-year survival rate has only improved marginally over the last decade. Late detection of the disease means that in most cases the disease has advanced locally and/or metastasized, and curative surgery is not possibl...

Full description

Saved in:
Bibliographic Details
Published in:Journal of experimental & clinical cancer research 2023-10, Vol.42 (1), p.280-16, Article 280
Main Authors: Wittwer, Nicole L, Brown, Michael P, Liapis, Vasilios, Staudacher, Alexander H
Format: Article
Language:English
Subjects:
Analog to digital converters
Antibodies
Antibodies, Monoclonal - therapeutic use
Antibody drug conjugate
Antigens
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biopharmaceutics
Bystander killing
Cancer
Cancer therapies
Cell cycle
Cell division
Chemotherapy
Cytotoxicity
Drug dosages
Epidermal growth factor
FDA approval
Health aspects
Humans
Immunoconjugates - pharmacology
Immunoconjugates - therapeutic use
Metastasis
Monoclonal antibodies
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Payloads
Review
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is one of the most common causes of cancer-related death, and the 5-year survival rate has only improved marginally over the last decade. Late detection of the disease means that in most cases the disease has advanced locally and/or metastasized, and curative surgery is not possible. Chemotherapy is still the first-line treatment however, this has only had a modest impact in improving survival, with associated toxicities. Therefore, there is an urgent need for targeted approaches to better treat pancreatic cancer, while minimizing treatment-induced side-effects. Antibody drug conjugates (ADCs) are one treatment option that could fill this gap. Here, a monoclonal antibody is used to deliver extremely potent drugs directly to the tumor site to improve on-target killing while reducing off-target toxicity. In this paper, we review the current literature for ADC targets that have been examined in vivo for treating pancreatic cancer, summarize current and on-going clinical trials using ADCs to treat pancreatic cancer and discuss potential strategies to improve their therapeutic window.
ISSN:1756-9966
0392-9078
1756-9966
DOI:10.1186/s13046-023-02868-x